ALL MARKETS
FTSE 100
FTSE 250
AIM MARKET


AstraZeneca PLC.
189 announcements.
Time Ticker Company Announcement
07:00 AZN AstraZeneca PLC
Farxiga approved in the US to reduce the risk of
07:00 AZN AstraZeneca PLC
Trastuzumab deruxtecan granted FDA Priority Review
15:04 AZN AstraZeneca PLC
Holding(s) in Company
15:00 AZN AstraZeneca PLC
Holding(s) in Company
07:00 AZN AstraZeneca PLC
Fasenra approved in the US for self-administration
16:00 AZN AstraZeneca PLC
Director Declaration
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:05 AZN AstraZeneca PLC
AstraZeneca divests rights for Losec to Cheplaphar
07:00 AZN AstraZeneca PLC
Update on US regulatory review of PT010 in COPD
15:30 AZN AstraZeneca PLC
Lynparza more than doubled the time without
07:00 AZN AstraZeneca PLC
Tagrisso is the only 1st-line treatment for EGFR-
07:00 AZN AstraZeneca PLC
Lynparza improved the time women lived without
07:00 AZN AstraZeneca PLC
Qtrilmet recommended for approval in EU by CHMP
07:00 AZN AstraZeneca PLC
AstraZeneca amends collaboration with Ironwood
08:38 AZN AstraZeneca PLC
Imfinzi is first immunotherapy to show both
07:11 AZN AstraZeneca PLC
Tagrisso approved in China as a 1st-line treatment
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:05 AZN AstraZeneca PLC
Brilinta reduced the risk of cardiovascular events
07:00 AZN AstraZeneca PLC
Detailed results from Phase III DAPA-HF trial
07:00 AZN AstraZeneca PLC
Anifrolumab Phase III trial meets primary endpoint
07:05 AZN AstraZeneca PLC
Fasenra granted US Orphan Drug Designation for
07:00 AZN AstraZeneca PLC
Breztri Aerosphere Phase III ETHOS trial met
07:00 AZN AstraZeneca PLC
AstraZeneca agrees to buy US FDA Priority Review
07:00 AZN AstraZeneca PLC
Roxadustat approved in China for the treatment of
07:00 AZN AstraZeneca PLC
Update on the Phase III NEPTUNE trial
07:00 AZN AstraZeneca PLC
Farxiga met primary endpoint in landmark Phase III
07:00 AZN AstraZeneca PLC
Directorate Change
07:00 AZN AstraZeneca PLC
Lynparza Phase III PAOLA-1 trial met primary endpo
07:00 AZN AstraZeneca PLC
Calquence granted US Breakthrough Therapy Designat
09:28 AZN AstraZeneca PLC
Amendment: Tagrisso significantly improves overall
07:00 AZN AstraZeneca PLC
Tagrisso significantly improves overall survival
07:00 AZN AstraZeneca PLC
Lynparza Phase III PROfound trial in HRR*
07:00 AZN AstraZeneca PLC
Forxiga label updated in the EU in type-2 diabetes
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
AZN: H1 2019 Results
07:00 AZN AstraZeneca PLC
Update on US regulatory decision for Farxiga
07:00 AZN AstraZeneca PLC
Imfinzi granted US Orphan Drug Designation for
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
Fasenra receives positive EU CHMP opinion for self
07:00 AZN AstraZeneca PLC
Forxiga receives positive EU CHMP opinion for
07:00 AZN AstraZeneca PLC
Imfinzi improves overall survival at interim
07:00 AZN AstraZeneca PLC
Lynparza approved in Japan for 1st-line
07:00 AZN AstraZeneca PLC
Breztri Aerosphere (PT010) approved in Japan for
07:00 AZN AstraZeneca PLC
Bevespi Aerosphere approved by the Japanese
07:00 AZN AstraZeneca PLC
Lynparza approved in the EU for 1st-line
07:00 AZN AstraZeneca PLC
Calquence significantly prolonged the time patient
16:45 AZN AstraZeneca PLC
Publication of a Prospectus
07:00 AZN AstraZeneca PLC
Calquence Phase III ELEVATE-TN trial met primary
12:36 AZN Hardman & Co Research
AstraZeneca: Where has all the cash gone?
15:00 AZN AstraZeneca PLC
Total Voting Rights
15:00 AZN AstraZeneca PLC
Block listing Interim Review
07:00 AZN AstraZeneca PLC
Lynparza nearly doubled time patients lived with
07:00 AZN AstraZeneca PLC
Pooled analyses of the roxadustat global Phase III
14:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
11:00 AZN AstraZeneca PLC
Director Declaration
07:00 AZN AstraZeneca PLC
Trastuzumab deruxtecan demonstrated clinically
07:00 AZN AstraZeneca PLC
Calquence PhIII ASCEND trial met primary endpoint
07:00 AZN AstraZeneca PLC
Qternmet XR approved in the US for type-2 diabetes
15:00 AZN AstraZeneca PLC
Total Voting Rights
12:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
07:00 AZN AstraZeneca PLC
Lynparza receives positive EU CHMP opinion for 1st
07:00 AZN AstraZeneca PLC
AZN: Q1 2019 Results
07:00 AZN AstraZeneca PLC
Lynparza approved in EU for the treatment of germl
13:30 AZN AstraZeneca PLC
Holding(s) in Company
10:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
15:00 AZN AstraZeneca PLC
Total Voting Rights
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
Selumetinib gets Breakthrough Therapy Designation
17:15 AZN AstraZeneca PLC
Results of Placing
07:00 AZN AstraZeneca PLC
AZ and Daiichi Sankyo enter collaboration in novel
07:00 AZN AstraZeneca PLC
Proposed placing of new ordinary shares
07:00 AZN AstraZeneca PLC
Forxiga approved in Japan for type-1 diabetes
07:00 AZN AstraZeneca PLC
Forxiga approved in Europe for type-1 diabetes
07:00 AZN AstraZeneca PLC
US FDA grants saracatinib ODD for IPF
12:00 AZN AstraZeneca PLC
Notice of AGM
12:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
07:00 AZN AstraZeneca PLC
Filing of Form 20-F with SEC
11:00 AZN AstraZeneca PLC
Annual Financial Report
15:00 AZN AstraZeneca PLC
Total Voting Rights
13:45 AZN AstraZeneca PLC
Lynparza receives positive EU CHMP opinion
07:00 AZN AstraZeneca PLC
Lynparza significantly delayed disease progression
07:00 AZN AstraZeneca PLC
Brilinta's PhIII THEMIS trial met primary endpoint
07:00 AZN AstraZeneca PLC
AstraZeneca Full-Year and Q4 2018 Results
07:00 AZN AstraZeneca PLC
US FDA grants Fasenra Orphan Drug Designation
07:05 AZN AstraZeneca PLC
US FDA grants Breakthrough Therapy Designation
07:00 AZN AstraZeneca PLC
EMA grants PRIME eligibility for MEDI8897
15:00 AZN AstraZeneca PLC
Total Voting Rights
13:17 AZN AstraZeneca PLC
Forxiga receives positive EU CHMP opinion
14:00 AZN AstraZeneca PLC
Completion of divestment of US Synagis rights
13:00 AZN AstraZeneca PLC
AstraZeneca announces organisational changes
15:00 AZN AstraZeneca PLC
Total Voting Rights
13:47 AZN AstraZeneca PLC
Bevespi Aerosphere approved in the EU for COPD
07:05 AZN AstraZeneca PLC
Lynparza meets primary endpoint in SOLO-3 trial
07:00 AZN AstraZeneca PLC
Phase III ROCKIES and OLYMPUS roxadustat trials
09:09 AZN AstraZeneca PLC
Roxadustat approved in China for the treatment of
07:00 AZN AstraZeneca PLC
Directorate Change
07:00 AZN AstraZeneca PLC
Update on the Phase III EAGLE trial of Imfinzi
07:00 AZN AstraZeneca PLC
Divestment of rights to Covis completed
15:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
16:00 AZN AstraZeneca PLC
Block listing Interim Review
16:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
Gr�nenthal Agreement for Nexium, Vimovo Completed
07:00 AZN AstraZeneca PLC
US FDA grants Fasenra ODD for EGPA
07:00 AZN AstraZeneca PLC
AstraZeneca provides update on Phase III MYSTIC
07:00 AZN AstraZeneca PLC
AstraZeneca to divest US Synagis rights to Sobi
07:00 AZN AstraZeneca PLC
Farxiga significantly reduced hospitalisation for
07:05 AZN AstraZeneca PLC
US FDA accepts regulatory submission for Lynparza
07:00 AZN AstraZeneca PLC
AZN: Year-to-Date and Q3 2018 Results
07:00 AZN AstraZeneca PLC
Divestment of rights to Covis Pharma
15:00 AZN AstraZeneca PLC
Total Voting Rights
09:45 AZN AstraZeneca PLC
Additional financial information-Gr�nenthal deal
07:00 AZN AstraZeneca PLC
Gr�nenthal Agreement for rights to Nexium, Vimovo
07:00 AZN AstraZeneca PLC
AstraZeneca Extends Innate Pharma Collaboration
07:00 AZN AstraZeneca PLC
Lynparza shows 70% reduction in PFS ovarian cancer
13:09 AZN AstraZeneca PLC
CHMP positive opinion Bevespi Aerosphere
07:00 AZN AstraZeneca PLC
FDA Orphan Drug for Lynparza in pancreatic cancer
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
Atacand Agreement with Cheplapharm Completed
16:00 AZN AstraZeneca PLC
Previous Announcement Regarding Appointment Of NED
13:15 AZN AstraZeneca PLC
Overall survival data for Imfinzi: Stage III NSCLC
16:10 AZN AstraZeneca PLC
EMA approves AZ's Imfinzi for Stage III NSCLC
07:00 AZN AstraZeneca PLC
Farxiga gets positive result in DECLARE-TIMI 58
07:00 AZN AstraZeneca PLC
FDA approves AZ's Lumoxiti in hairy cell leukaemia
07:00 AZN AstraZeneca PLC
Tezepelumab FDA Breakthrough Therapy Designation
07:00 AZN AstraZeneca PLC
Directorate Change
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
AstraZeneca Update on Anifrolumab in SLE
07:00 AZN AstraZeneca PLC
EC approves Bydureon BCise device for T2 diabetes
07:00 AZN AstraZeneca PLC
AstraZeneca PIIIb trial update for Bevespi in COPD
07:00 AZN AstraZeneca PLC
AZ's Tagrisso approved in Japan for 1st-line NSCLC
07:00 AZN AstraZeneca PLC
AstraZeneca prices a $3bn bond issue
07:00 AZN AstraZeneca PLC
EMA grants OD for selumetinib in NF1
15:00 AZN AstraZeneca PLC
Total Voting Rights
14:00 AZN AstraZeneca PLC
CHMP recommends Imfinzi for Stage III nsclc
07:00 AZN AstraZeneca PLC
AZN: H1 2018 Results
07:00 AZN AstraZeneca PLC
Atacand to be divested to Cheplapharm in Europe
12:00 AZN AstraZeneca PLC
Holding(s) in Company
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
Lynparza approved in Japan for BRCAm breast cancer
07:00 AZN AstraZeneca PLC
Imfinzi approved in Japan for Stage III nsclc
15:00 AZN AstraZeneca PLC
Bydureon receives positive CHMP opinion for BCise
13:30 AZN AstraZeneca PLC
AZ and Luye Pharma complete agreement for Seroquel
07:00 AZN AstraZeneca PLC
Lynparza: significant PFS 1st-line ovarian cancer
07:00 AZN AstraZeneca PLC
Board Committee Changes
07:00 AZN AstraZeneca PLC
Publication of a Prospectus
07:00 AZN AstraZeneca PLC
Update: lanabecestat Phase III Alzheimer's trials
17:30 AZN AstraZeneca PLC
EU APPROVES TAGRISSO FOR 1ST-LINE NSCLC
07:00 AZN AstraZeneca PLC
Director Declaration
15:00 AZN AstraZeneca PLC
Block listing Interim Review
15:00 AZN AstraZeneca PLC
Total Voting Rights
11:00 AZN AstraZeneca PLC
Director Declaration
07:00 AZN AstraZeneca PLC
Update on TERRANOVA PIII trial for Fasenra in COPD
07:00 AZN AstraZeneca PLC
AZ's Imfinzi: significant OS in Stage III nsclc
07:00 AZN AstraZeneca PLC
AZ regulatory submission in Japan for Forxiga
07:00 AZN AstraZeneca PLC
US FDA approves Lokelma for adult hyperkalaemia
17:30 AZN AstraZeneca PLC
Result of AGM
07:00 AZN AstraZeneca PLC
AZN: Q1 2018 Results
15:00 AZN AstraZeneca PLC
Total Voting Rights
15:10 AZN AstraZeneca PLC
AstraZeneca's Fasenra approved in the EU
16:10 AZN AstraZeneca PLC
FDA approves Lynparza for metastatic breast cancer
07:00 AZN AstraZeneca PLC
ASTRAZENECA'S FASENRA RECEIVES APPROVAL IN JAPAN
07:00 AZN AstraZeneca PLC
LYNPARZA APPROVED IN JAPAN FOR OVARIAN CANCER
18:20 AZN AstraZeneca PLC
AZ Reports Phase III Results for PT010 in COPD
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
AZN: Full-Year 2017 Results
14:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
07:00 AZN AstraZeneca PLC
Selumetinib in NF1 gets FDA orphan drug status
07:00 AZN AstraZeneca PLC
AstraZeneca's IMFINZI approved for Stage III nsclc
12:35 AZN AstraZeneca PLC
Lynparza CHMP for ovarian cancer maintainance
15:00 AZN AstraZeneca PLC
Total Voting Rights
11:00 AZN AstraZeneca PLC
Annual Financial Report
07:00 AZN AstraZeneca PLC
Filing of Form 20-F with SEC
07:00 AZN AstraZeneca PLC
ASTRAZENECA UPDATES MYSTIC TRIAL TIMELINE
16:48 AZN AstraZeneca PLC
Lokelma approved in the EU
15:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
15:00 AZN AstraZeneca PLC
Director/PDMR Shareholding
15:00 AZN AstraZeneca PLC
Total Voting Rights
07:00 AZN AstraZeneca PLC
AZ AND MSD SUBMIT LYNPARZA FOR BREAST CANCER IN EU
07:00 AZN AstraZeneca PLC
FDA TO REVIEW MOXETUMOMAB FOR HAIRY CELL LEUKAEMIA
07:00 AZN AstraZeneca PLC
Directorate Change
11:00 AZN AstraZeneca PLC
Notice of AGM
07:00 AZN AstraZeneca PLC
FDA approves Tagrisso for 1st-line use in NSCLC
07:00 AZN AstraZeneca PLC
AstraZeneca:high level results of the ARCTIC trial
12:30 AZN AstraZeneca PLC
AZ: positive CHMP for Tagrisso first-line nsclc
15:00 AZN AstraZeneca PLC
Total Voting Rights
12:00 AZN AstraZeneca PLC
Director Declaration
11:00 AZN AstraZeneca PLC
EMA approves Lynparza: maintenance ovarian cancer
07:00 AZN AstraZeneca PLC
AZ and Luye Pharma enter agreement for Seroquel
07:00 AZN AstraZeneca PLC
AstraZeneca update on Fasenra PIII trial in COPD